www.tickerreport.com ·
Capstone Capital Management Ltd Makes New 978000 Investment in United Therapeutics Corporation Uthr
Topic context
This topic has been covered 255148 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe news is about institutional investment activity in United Therapeutics, a biotech/pharma company. The commercial mechanism is weak: it reflects portfolio rebalancing by a small fund, not a change in the company's fundamentals, product pipeline, or supply chain. No scarcity, demand shock, or margin impact is indicated. The sector is PHARMA_BIOTECH but the signal is minimal.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Capstone Capital Management Ltd invested $978,000 in United Therapeutics (UTHR) by purchasing 2,008 shares in Q4.
- United Therapeutics reported Q4 revenue of $781.50 million, missing analyst estimates.
- Earnings per share were $5.82, below the expected $7.00.
- Insiders sold 530,913 shares valued at $294.8 million over the last quarter.
- Stock opened at $566.99 with a market cap of $24.07 billion.
United Therapeutics stock is likely to face downward pressure of 3-5% within 48 hours due to significant insider selling and an earnings miss.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
marketscreener.com